Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
AUTOR(ES)
Santos, Fabio Pires de Souza; Tavares, Renato Sampaio; Pagnano, Katia Borgia Barbosa
FONTE
Hematol., Transfus. Cell Ther.
DATA DE PUBLICAÇÃO
2020-09
RESUMO
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.
Documentos Relacionados
- Elective Colorectal Surgery Service Provision during SARS-CoV-2 Pandemic
- The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak
- Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis
- Grupo de Estudos da Doença Inflamatória Intestinal do Brasil sobre a vacinação para SARS-CoV2
- Olfactory and Taste Disorders in Patients with SARS-CoV-2 Infection